Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Resource Type
Article
Authors
Chan, Arlene ; Delaloge, Suzette ; Holmes, Frankie A ; Moy, Beverly ; Iwata, Hiroji ; Harvey, Vernon J ; Robert, Nicholas J ; Silovski, Tajana ; Gokmen, Erhan ; von Minckwitz, Gunter ; Ejlertsen, Bent ; Chia, Stephen K L ; Mansi, Janine ; Barrios, Carlos H ; Gnant, Michael ; Buyse, Marc ; Gore, Ira ; Smith, John, II ; Harker, Graydon ; Masuda, Norikazu ; Petrakova, Katarina ; Zotano, Angel Guerrero ; Iannotti, Nicholas ; Rodriguez, Gladys ; Tassone, Pierfrancesco ; Wong, Alvin ; Bryce, Richard ; Ye, Yining ; Yao, Bin ; Martin, Miguel
Source
In The Lancet Oncology March 2016 17(3):367-377
Subject
Primary Research Articles
Language
ISSN
1470-2045